Northwire Canada EditionTuesday, August 25, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4697.80 +0.4% SILVER 68.59 −1.4% COPPER 6.61 +0.3% OIL 85.01 −2.4% PALLADIUM 1359.75 +0.7% NVO 0.070 +0.0% SRA 0.780 +0.0% TUK 0.020 −20.0% GWM 0.610 −4.7% MINE 0.110 +0.0% EGM 0.100 +0.0% IRO 1.11 +2.8% CBR 1.41 +2.5% CTN 0.045 +0.0% GMX 2.06 +2.0% NPR 0.700 −2.8% CGD 1.28 +8.5% CRE 0.390 +13.0% PE 0.250 +0.0% PER 0.150 +7.1% SVRS 0.540 +8.0% GOLD 4697.80 +0.4% SILVER 68.59 −1.4% COPPER 6.61 +0.3% OIL 85.01 −2.4% PALLADIUM 1359.75 +0.7% NVO 0.070 +0.0% SRA 0.780 +0.0% TUK 0.020 −20.0% GWM 0.610 −4.7% MINE 0.110 +0.0% EGM 0.100 +0.0% IRO 1.11 +2.8% CBR 1.41 +2.5% CTN 0.045 +0.0% GMX 2.06 +2.0% NPR 0.700 −2.8% CGD 1.28 +8.5% CRE 0.390 +13.0% PE 0.250 +0.0% PER 0.150 +7.1% SVRS 0.540 +8.0%
Other Routine +

Bausch + Lomb Launches PreserVision AREDS3(TM) Eye Vitamins in the United States

Bausch + Lomb Executes H1 2026 Launch Plan Amidst Margin Expansion Push

By The Northwire Desk — AI Analysis May 19, 2026 · 07:00 BLCO · 21.98 BAUSCH + LOMB CORPORATION
Executive Summary
  • Bausch + Lomb announced the U.S. launch of PreserVision AREDS3 eye vitamins on May 19, 2026.
  • The new formula combines clinically proven AREDS2 nutrients with a proprietary B-vitamin complex (B1, B2, B3, B5, B6, B7, B9, B12).
  • Designed for individuals in earlier stages of age-related macular degeneration (AMD), expanding the addressable market from 11 million to 28 million patients.
  • Product is available at major national retailers including Amazon, Target, Walgreens, and Walmart.
  • Clinical foundation includes a narrative review synthesizing over 20 human studies involving nearly 30,000 individuals.
  • Company plans for a future long-term clinical trial to evaluate the AREDS3 formulation efficacy.
Material Impact
  • The launch was explicitly anticipated in the November 2025 Investor Day presentation which listed PreserVision AREDS3 as an H1 2026 consumer segment launch.
  • Previous news on April 23, 2026 announced the published review and intent to launch, making this execution rather than new information.
  • Revenue impact is incremental; while it expands the AMD portfolio, supplements face high competition and pricing pressure compared to prescription pharmaceuticals like MIEBO or XIIDRA.
  • No change to full-year guidance was issued with this release; financial targets remain aligned with Q1 2026 raised guidance ($5.42B-$5.52B revenue).
  • The news confirms management is executing on the "Vision '27" transformation plan but does not alter the fundamental investment thesis or risk profile significantly.
BLCO · Price
Company Overview
  • Flagship Projects: MIEBO (dry eye), XIIDRA (lifitegrast ophthalmic solution), enVista IOLs (intraocular lenses), Stellaris Elite Surgical System.
  • Business Segments: Vision Care (Contact Lenses, OTC), Pharmaceuticals (Dry Eye treatments), Surgical (IOLs, Equipment).
  • Pipeline: $7 billion peak-sales pipeline projected across consumer, pharmaceutical, surgical and contact-lens segments through 2031.
  • Key Assets: LUMIFY holds ~70% U.S. redness relief market share; MIEBO and XIIDRA driving pharmaceutical growth phase.
  • Strategic Focus: "Vision '27" initiative targeting margin expansion to ~23% adjusted EBITDA by 2028.
Read the original news release →

More from BAUSCH + LOMB CORPORATION

Jul 01, 2026 · 07:00

Dry Eye Survey Reinforces Premium Pricing Power, But Lacks Catalyst to Break Recent Consolidation

Other Jun 01, 2026 · 06:59

Bausch + Lomb Expands Dry Eye Portfolio with Preservative-Free Blink Launch; Execution on $7B Pipeline Continues Amid Margin Expansion

Financings May 07, 2026 · 07:00

Bausch + Lomb Expands Surgical Portfolio with European Bi-Blade+ Launch Amidst Guidance Raise

Other May 06, 2026 · 07:15

Bausch + Lomb Pipeline Webinar Confirms Long-Term Growth Narrative, But Near-Term Surgical Headwinds Persist Despite Q1 Guidance Raise

Other Apr 30, 2026 · 07:00

Bausch + Lomb Pipeline Validation Follows Q1 Guidance Raise Amidst Margin Expansion

Other Apr 29, 2026 · 06:58

Bausch + Lomb Beats Q1 Estimates but Debt Overhang Persists Amid Turnaround Execution

Earnings